BG Technology
Kassmannhuber J, Rauscher M, Schöner L, Witte A, Lubitz W. 2017. Functional display of ice nucleation protein InaZ on the surface of bacterial ghosts. Bioengineered, Jan 25:1-13.
Meitz A, Sagmeister P, Lubitz W, Herwig C, Langemann T. 2016. Fed-Batch Production of Bacterial Ghosts Using Dielectric Spectroscopy for Dynamic Process Control. Microorganisms. 2016 Mar 24;4(2).
Langemann T, Mayr UB, Meitz A, Lubitz W, Herwig C. 2016. Multi-parameter flow cytometry as a process analytical technology (PAT) approach for the assessment of bacterial ghost production. Appl Microbiol Biotechnol. 2016 Jan;100(1):409-18.
Montanaro J, Inic-Kanada A, Ladurner A, Stein E, Belij S, Bintner N, Schlacher S, Schuerer N, Mayr UB, Lubitz W, Leisch N, Barisani-Asenbauer T. 2015. Escherichia coli Nissle 1917 bacterial ghosts retain crucial surface properties and express chlamydial antigen: an imaging study of a delivery system for the ocular surface. Drug Des Devel Ther. 2015 Jul 21;9:3741-54.
Inic-Kanada A, Stojanovic M, Schlacher S, Stein E, Belij-Rammerstorfer S, Marinkovic E, Lukic I, Montanaro J, Schuerer N, Bintner N, Kovacevic-Jovanovic V, Krnjaja O, Mayr UB, Lubitz W, Barisani-Asenbauer T. 2015. Delivery of a Chlamydial Adhesin N-PmpC Subunit Vaccine to the Ocular Mucosa Using Particulate Carriers. PLoS One. 2015 Dec 11;10(12).
Stein E, Inic-Kanada A, Belij S, Montanaro J, Bintner N, Schlacher S, Mayr UB, Lubitz W, Stojanovic M, Najdenski H, Barisani-Asenbauer T. 2013. In vitro and in vivo uptake study of Escherichia coli Nissle 1917 bacterial ghosts: cell-based delivery system to target ocular surface diseases. Invest Ophthalmol Vis Sci. 2013 Sep 24;54(9):6326-33
Koller VJ, Dirsch VM, Beres H, Donath O, Reznicek G, Lubitz W, Kudela P. 2013. Modulation of bacterial ghosts-induced nitric oxide production in macrophages by bacterial ghost-delivered resveratrol. FEBS J. 2013 Mar: 280 (5):1214-25.
Langemann, T., Koller, V.J., Muhammad, A., Kudela, P. , Mayr, U.B., Lubitz, W.: The bacterial ghost platform system: Production and applications. Bioengineered Bugs, 1(5):326-336, 2010.
Paukner S., T. Stiedl, P. Kudela, J. Bizik, F. Al Laham, W. Lubitz. 2006. Bacterial ghosts as a novel advanced targeting system for drug and DNA delivery. Expert Opin. Drug Deliv. 3:11-22.
Haidinger, W., U.B. Mayr, M. Szostak, S. Resch, W. Lubitz. 2003. Escherichia coli ghost production by expression of lysis gene E and staphylococcal nuclease. Appl. Environment. Microbiol. 69:6106-6113.
Jechlinger, W., Haidinger, W., Paukner, S., Mayrhofer, P., Riedman, E., Marchart, J., Mayr, U., Haller, C., Kohl, G., Walcher, P., Kudela, P., Bizik, J., Felnerova, D., Denner, E.M.B., Indra, A., Haslberger, A., Szostak, M., Resch, S., Eko, F., Schukovskaya, T., Kutyrev, V., Hensel, A., Friederisch, S., Schlapp, T., Lubitz, W.: Bacterial ghosts as carrier and targeting systems for antigen delivery. In: Vaccine Delivery Strategies, Dietrich G. and Goebel W., eds. Horizon Scientific Press, Wymondham, Norfolk, UK, pp. 163-184, 2002.
Jechlinger, W., M. Szostak, A. Witte, W. Lubitz. 1999. Altered temperature induction sensitivity of the lambda PR/cI857 system for controlled gene E-expression in Escherichia coli. FEMS Microbiol. Lett. 173: 347-352.
Jechlinger, W., M. Szostak, W. Lubitz. 1998. Cold-sensitive E-lysis systems. Gene 218:1-7.
Witte, A., G. Wanner, W. Lubitz, J.-V. Höltje. 1998. Effect of PhiX174 protein E-mediated lysis on murein composition of Escherichia coli. FEMS Microbiol. Lett., 164: 149-157.
Witte, A., G. Wanner, U. Bläsi, G. Halfmann, M.P. Szostak, W. Lubitz. 1990. Endogenous transmembrane tunnel formation mediated by PhiX174 lysis protein E. J. Bacteriol. 172:4109-4114.
Reviews
Muhammad, A., Champeimont, J., Mayr, U.B., Lubitz, W., Kudela, P. Bacterial ghosts as carriers of protein subunit and DNA-encoded antigens for vaccine applications. Expert Rev Vaccines, 11(1):97-116, 2012.
Kudela, P., Koller, V.J., Lubitz, W.: Bacterial Ghosts (BGs) – Advanced Antigen and Drug Delivery System. Vaccine, 28(36):5760-5767, 2010.
Mayr, U. B., V. J. Koller, P. Lubitz and W. Lubitz, Bacterial ghosts as vaccine and drug delivery platforms, in Patho-Biotechnology, R. Sleator and C. Hill, Editors. 2009, Landes Bioscience: Austin, Texas, USA. p. 50-59.
Lubitz P., U.B. Mayr, W. Lubitz. 2009. Applications of bacterial ghosts in biomedicine. Adv. Exp. Med. Biol. 655:159-70.
Riedmann, E., J.M. Kyd, A. W. Cripps, W. Lubitz. 2007. Bacterial ghosts as adjuvant particles. Expert Rev. Vaccines 6: 241-253.
Mayr, U.B., P. Walcher, C. Azimpour, E. Riedmann, C. Haller, W. Lubitz. 2005. Bacterial ghosts as delivery vehicles for vaccination against target antigens. Adv. Drug Delivery Rev, 57:1381-1391.
Walcher, P., U.B. Mayr, C. Azimpour-Tabrizi, F.O. Eko, W. Jechlinger, P. Mayrhofer, T. Alefantis, C.V. Mujer, V. DelVecchio, W. Lubitz. 2004. Antigen discovery and delivery of subunit vaccines by nonliving bacterial ghost vectors. Exp. Rev. Vaccines 3:681-691.
Felnerova, D., Kudela, P., Bizik, J., Haslberger, A., Hensel, A., Saalmuller, A., Lubitz, W.: T cell-specific immune response induced by bacterial ghosts. Med Sci Monit, 10(10):362-370, 2004.
Azimpour Tabrizi, C., P. Walcher, U.B. Mayr, T. Stiedl, M. Binder, J. McGrath, W. Lubitz.2004. Bacterial Ghosts – Biological particles as delivery systems for antigens, nucleic acids and drugs. Current Opinion Biotech 15:530-537.
Lubitz, W. 2001. Bacterial ghosts as carrier and targeting systems. Expert Opin. Biol. Ther. 1:765-771.
Eko, F.O., A. Witte, V. Huter, B. Kuen, S. Fürst-Ladani, A. Haslberger, A. Katinger, A. Hensel. M.P. Szostak, S. Resch, H. Mader, P. Raza, E. Brand, J. Marchart, W. Jechlinger, W. Haidinger, W. Lubitz. 1999. New strategies for combination vaccines based on the extended recombinant bacterial ghost system. Vaccine 17: 1643-1649.